What is Biorce?
Biorce operates at the intersection of artificial intelligence and clinical research, offering its flagship platform, Aika, to address systemic inefficiencies in drug development. The platform is engineered to automate protocol creation, conduct rigorous feasibility analysis, and optimize regulatory planning. By reducing the frequency of protocol amendments and lowering operational overhead, Biorce enables clinical teams across the US, EU, and APAC regions to accelerate the delivery of life-saving treatments to patients.
The company's market position is defined by its commitment to precision and efficiency. By leveraging deep expertise in both clinical research and machine learning, Biorce provides a scalable solution that addresses the high-stakes requirements of modern pharmaceutical trials. As the industry faces increasing pressure to reduce time-to-market, Biorce's AI-native approach serves as a vital catalyst for innovation in the global healthcare value chain.
How much funding has Biorce raised?
Biorce has raised a total of $94.9M across 3 funding rounds:
Other Financing Round
$37M
Other Financing Round
$5.9M
Series A
$52M
Other Financing Round (2024): $37M with participation from Plug and Play Tech Center, YZR Capital, and MSM fund (Mustard Seed Maze
Other Financing Round (2025): $5.9M led by Norrsken Vc
Series A (2026): $52M supported by Norrsken Vc, MSM fund (Mustard Seed Maze, YZR Capital, and DST Global
Key Investors in Biorce
Norrsken Vc
Norrsken VC is Europe's leading early-stage impact investor, focusing on companies that address significant global challenges while achieving substantial business growth.
DST Global
DST Global is a prominent international investment group that focuses exclusively on the internet and technology-enabled companies, providing strategic support to market leaders.
MSM fund (Mustard Seed Maze)
MSM Impact VC Fund is an investment firm focused on supporting fast-growing European ventures that address social and environmental challenges through sustainable business models.
What's next for Biorce?
With the successful closure of this Series A round, Biorce is well-positioned to accelerate its international expansion and deepen its product capabilities. The strategic capital will likely be deployed to enhance the Aika platform's predictive analytics, further reducing the friction associated with complex regulatory environments. As the company scales, it will focus on solidifying its footprint in key global markets, ensuring that its AI-driven tools become the standard for clinical trial excellence.
Looking ahead, Biorce is expected to leverage its robust investor network to forge deeper partnerships with global pharmaceutical leaders. By maintaining its focus on measurable impact and operational efficiency, the firm is poised to redefine the future of drug development, transforming how clinical trials are designed, executed, and monitored on a global scale.
